CONTEXT: Visceral adiposity is a strong determinant of GH secretion, and low endogenous GH secretion is associated with increased insulin resistance, a key component of the metabolic syndrome. Increased fat accumulation in skeletal muscle and liver may play an etiological role in the development of insulin resistance and other complications of the metabolic syndrome. Little is known about the role of decreased endogenous GH secretion in the pathogenesis of insulin resistance in obesity. OBJECTIVE: To investigate the relationship between intramyocellular lipids (IMCL), intrahepatic lipids, and peak-stimulated GH in premenopausal women with obesity. DESIGN AND SETTING: We conducted a cross-sectional study at a clinical translational research center. PATIENTS: Patients included 21 premenopausal women with obesity (mean body mass index, 34.0 +/- 4.5 kg/m(2)) and 17 normal-weight controls (mean body mass index, 21.9 +/- 2.0 kg/m(2)) of comparable mean age. MAIN OUTCOMES MEASURES: IMCL and intrahepatic lipids were measured with proton magnetic resonance spectroscopy ((1)H-MRS). Body composition was measured with magnetic resonance imaging. Peak GH was measured after stimulation with GHRH-arginine. RESULTS: Obese subjects had higher IMCL, intrahepatic lipids, abdominal and thigh fat, and thigh muscle mass compared with normal-weight controls. There were strong inverse associations between peak GH and both IMCL and intrahepatic lipids independent of age and visceral adiposity. There were positive associations between IMCL and intrahepatic lipids with measures of insulin resistance and serum triglycerides. CONCLUSION: In premenopausal women with obesity, peak GH is inversely associated with IMCL and intrahepatic lipids independent of age and visceral adiposity. This suggests that low GH may contribute to insulin resistance in obesity through effects on muscle and intrahepatic lipids.
CONTEXT: Visceral adiposity is a strong determinant of GH secretion, and low endogenous GH secretion is associated with increased insulin resistance, a key component of the metabolic syndrome. Increased fat accumulation in skeletal muscle and liver may play an etiological role in the development of insulin resistance and other complications of the metabolic syndrome. Little is known about the role of decreased endogenous GH secretion in the pathogenesis of insulin resistance in obesity. OBJECTIVE: To investigate the relationship between intramyocellular lipids (IMCL), intrahepatic lipids, and peak-stimulated GH in premenopausal women with obesity. DESIGN AND SETTING: We conducted a cross-sectional study at a clinical translational research center. PATIENTS: Patients included 21 premenopausal women with obesity (mean body mass index, 34.0 +/- 4.5 kg/m(2)) and 17 normal-weight controls (mean body mass index, 21.9 +/- 2.0 kg/m(2)) of comparable mean age. MAIN OUTCOMES MEASURES: IMCL and intrahepatic lipids were measured with proton magnetic resonance spectroscopy ((1)H-MRS). Body composition was measured with magnetic resonance imaging. Peak GH was measured after stimulation with GHRH-arginine. RESULTS: Obese subjects had higher IMCL, intrahepatic lipids, abdominal and thigh fat, and thigh muscle mass compared with normal-weight controls. There were strong inverse associations between peak GH and both IMCL and intrahepatic lipids independent of age and visceral adiposity. There were positive associations between IMCL and intrahepatic lipids with measures of insulin resistance and serum triglycerides. CONCLUSION: In premenopausal women with obesity, peak GH is inversely associated with IMCL and intrahepatic lipids independent of age and visceral adiposity. This suggests that low GH may contribute to insulin resistance in obesity through effects on muscle and intrahepatic lipids.
Authors: Claus Thamer; Jürgen Machann; Oliver Bachmann; Michael Haap; Dominik Dahl; Beate Wietek; Otto Tschritter; Andreas Niess; Klaus Brechtel; Andreas Fritsche; Claus Claussen; Stephan Jacob; Fritz Schick; Hans-Ulrich Häring; Michael Stumvoll Journal: J Clin Endocrinol Metab Date: 2003-04 Impact factor: 5.958
Authors: Miriam A Bredella; Andrea L Utz; Martin Torriani; Bijoy Thomas; David A Schoenfeld; Karen K Miller Journal: J Appl Physiol (1985) Date: 2008-12-18
Authors: Beverly M K Biller; Mary H Samuels; Anthony Zagar; David M Cook; Baha M Arafah; Vivien Bonert; Stavros Stavrou; David L Kleinberg; John J Chipman; Mark L Hartman Journal: J Clin Endocrinol Metab Date: 2002-05 Impact factor: 5.958
Authors: Miriam A Bredella; Eleanor Lin; Danielle J Brick; Anu V Gerweck; Lindsey M Harrington; Martin Torriani; Bijoy J Thomas; David A Schoenfeld; Anne Breggia; Clifford J Rosen; Linda C Hemphill; Zida Wu; Nader Rifai; Andrea L Utz; Karen K Miller Journal: Eur J Endocrinol Date: 2012-01-24 Impact factor: 6.664
Authors: Miriam A Bredella; Pouneh K Fazeli; Scott M Daley; Karen K Miller; Clifford J Rosen; Anne Klibanski; Martin Torriani Journal: Bone Date: 2014-06-19 Impact factor: 4.398
Authors: Miriam A Bredella; Anu V Gerweck; Lauren A Barber; Anne Breggia; Clifford J Rosen; Martin Torriani; Karen K Miller Journal: Bone Date: 2014-02-05 Impact factor: 4.398
Authors: Miriam A Bredella; Melanie Schorr; Laura E Dichtel; Anu V Gerweck; Brian J Young; Whitney W Woodmansee; Brooke Swearingen; Karen K Miller Journal: J Clin Endocrinol Metab Date: 2017-11-01 Impact factor: 5.958
Authors: Miriam A Bredella; Corey M Gill; Anu V Gerweck; Melissa G Landa; Vidhya Kumar; Scott M Daley; Martin Torriani; Karen K Miller Journal: Radiology Date: 2013-07-16 Impact factor: 11.105